| Oryzon

Skip to main content

English
Español

Company
- Overview
- Strategy
- Team
Epigenetics
- Epigenetics
- LSD1
Programs
Patients
- Clinical Trials
Investors
News & Events
- Press releases
- Events
Contact

Search

Breadcrumb

Home

3 April 2020

ORYZON presents efficacy data from its two vafidemstat clinical trials in Alzheimer’s disease at the virtual AAT-AD/PD 2020 Conference

19-20 February 2020

13th Annual European LifeSciences CEO Forum

Zurich

Switzerland

10-11 February 2020

22nd BIO CEO & Investor Conference

New York Marriott Marquis

NY

United States

4-5 February 2020

6th Annual LSX World Congress 2020

133 Houndsditch, Liverpool St

London

United Kingdom

28 January 2020

BioMed Event

Les Salons Hoche, 9 Avenue Hoche

Paris

France

27 January 2020

ORYZON to present at upcoming international conferences

8 January 2020

ORYZON to present at the 3rd Neuroscience Innovation Forum in San Francisco

9 December 2019

ORYZON presents new efficacy data from its Phase II trial ALICE investigating iadademstat in AML

2 December 2019

ORYZON to present at upcoming international conferences

11 November 2019

ORYZON to present at upcoming international conferences

Pagination

First page «
Previous page ‹
Page 29
Page 30
Page 31
Page 32
Current page 33
Page 34
Page 35
Page 36
Page 37
Next page ›
Last page »

Subscribe to

Company

Overview
Strategy
Team

Epigenetics

Epigenetics
LSD1

Programs

Pipeline
Iadademstat
Vafidemstat
Collaborations
Publications

Patients

Clinical Trials

Investors

Share Information
Financial Information
CNMV Filings
Analyst Coverage
Corporate Governance
Corporate Social Responsibility

News & Events

Press releases
Events

Contact

Contact
Email Alerts
Join us

© Oryzon Genomics, S.A. - All Rights Reserved

Legal
Privacy Policy
Cookie Policy
Ethics Channel